Regulatory
Tirzepatide Compounding Regulation
Compounding is governed by a federal framework distinguishing 503A pharmacies from 503B outsourcing facilities, layered with state board licensure. Compounding a copy of an approved drug is restricted, with drug-shortage status historically a significant factor. Because regulatory positions in this area have changed repeatedly, current status should be checked at the source.
Key takeaways
- Federal law distinguishes 503A compounding pharmacies from 503B outsourcing facilities.
- State boards of pharmacy licence and discipline compounding pharmacies.
- Compounding copies of approved drugs is restricted, with shortage status a historically significant factor.
- Regulatory positions on compounded incretins have changed repeatedly.
- Check current status at the source rather than relying on any secondary summary, including this one.
| Federal framework | 503A pharmacies and 503B outsourcing facilities |
|---|---|
| State role | Licensure and discipline through boards of pharmacy |
| Copies of approved drugs | Restricted, with defined exceptions |
| Shortage relevance | Historically significant to permissible compounding |
| Volatility | Regulatory positions have changed repeatedly |
| Verification | Check FDA and state board sources directly |
What does the framework actually restrict?
Broadly, compounding is intended to meet needs approved products cannot serve, so producing what amounts to a copy of a commercially available approved drug is restricted rather than freely permitted. Drug-shortage status has historically been a significant factor in what compounding is permissible, because a shortage means the approved product is not actually available.
This is why shortage status and compounded supply have been so closely linked in this category, and why changes to shortage designations have had immediate commercial consequences.
What does regulation not do?
It does not approve compounded products, test their effectiveness, or verify individual preparations. Facility oversight — licensure, registration, inspection — governs how an operation runs, not whether a given vial contains what it should.
This is the gap that pharmacy verification partially fills for a consumer, and that trial evidence would fill if it existed.
How should a consumer track this?
Through FDA communications and state board records rather than provider marketing, which has an obvious interest in characterising the position favourably. Any provider statement about the regulatory status of compounded tirzepatide is worth checking against a primary source before relying on it.
What the evidence shows
- That a federal framework distinguishes compounding categories and states licence pharmacies.
- That restrictions apply to compounding copies of approved drugs.
What the evidence does not show
- The current regulatory position at the time you read this — check primary sources.
- That any regulatory status makes a compounded product approved.
Related: 503A versus 503B · Availability and supply
What exactly differs between approved and compounded tirzepatide?
| Attribute | FDA-approved (Zepbound / Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Premarket FDA review | Yes — safety, efficacy, and quality reviewed | No |
| Randomised trial evidence | SURMOUNT and SURPASS programmes | None identified |
| Concentration | Fixed and verified by the manufacturer | Varies by pharmacy; not independently verified |
| Presentation | Fixed-dose pen or autoinjector | Commonly a vial requiring measurement |
| Dating | Manufacturer expiry from stability testing | Pharmacy-assigned beyond-use date |
| Adverse-event capture | Systematic post-marketing surveillance | Less systematic |
| Consumer verification route | FDA approval record | State board licence lookup |
| Group | FDA-approved | Compounded |
|---|---|---|
| Randomised trials | 6 | 0 |
| Verified concentration | 1 | 0 |
| Premarket review | 1 | 0 |
What is the regulatory timeline for compounded tirzepatide?
The compounding of tirzepatide was permitted only because the drug appeared on the FDA drug shortage list. Once the shortage was resolved, the legal basis for compounding an essentially-a-copy version ended. The sequence below is the documented chain of that change, each step verifiable against the sources listed at the foot of this page.
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list amid surging demand. |
| 2024-10-02 | FDA removes tirzepatide from the drug shortage list, determining supply can meet national demand. |
| 2024-10-11 | Court remands the decision to the FDA for reevaluation after the Outsourcing Facilities Association and FarmaKeio sue. |
| 2024-12-19 | FDA issues a declaratory order reaffirming the tirzepatide shortage is resolved, with grace periods for compounders. |
| 2025-02-18 | Enforcement discretion ends for 503A state-licensed pharmacies compounding tirzepatide injection. |
| 2025-03-19 | Enforcement discretion ends for 503B outsourcing facilities compounding tirzepatide injection. |
| 2025-05 | US District Court for the Northern District of Texas upholds the FDA's shortage resolution. |
| 2026-02-06 | FDA announces steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved products. |
| Product | Regulatory status | What that means for availability |
|---|---|---|
| Zepbound (tirzepatide) | FDA approved for chronic weight management | Available by prescription through normal pharmacy channels |
| Mounjaro (tirzepatide) | FDA approved for type 2 diabetes | Available by prescription through normal pharmacy channels |
| Compounded tirzepatide injection | Not FDA approved; shortage resolved, enforcement discretion ended | Routine compounding no longer permitted as an essentially-a-copy product |
| Compounded oral, sublingual, ODT or troche tirzepatide | Not FDA approved in any form | Never covered by shortage-era compounding; no approved oral tirzepatide product exists |
| Research-grade or grey-market tirzepatide | Not a medicine; outside the regulated supply chain | No pharmacy accountability, no verified identity, purity, or sterility |
What does this mean if you are buying or already using compounded tirzepatide?
The practical consequences differ depending on whether you are considering starting, already receiving a compounded product, or comparing prices. None of the following is legal advice, and none of it is a reason to stop a prescribed medicine without speaking to the prescriber who issued it.
- Compounded tirzepatide marketed as an equivalent of Zepbound or Mounjaro is generally no longer permitted.
- Some sellers continue to market 'personalised' compounded tirzepatide by adding ingredients such as vitamin B12 or altering the dose. The FDA treats products within a narrow range of the approved dose as essentially copies.
- Any seller still advertising compounded tirzepatide should be treated as a significant verification question, not a bargain.
- Oral, sublingual, ODT, and troche tirzepatide have never been FDA approved in any form and were never covered by shortage-era compounding.
- Patients previously using compounded tirzepatide should discuss transition to an approved product with a prescriber.
The most useful single question to ask any seller still advertising compounded tirzepatide is what legal basis it is operating under, and which state-licensed pharmacy is dispensing. A seller that cannot answer both clearly is not a seller whose product can be verified.
What does the regulatory framework actually say?
Compounding occupies a specific legal position that is frequently described inaccurately in marketing. A 503A pharmacy prepares patient-specific preparations against individual prescriptions and is licensed by a state board of pharmacy. A 503B outsourcing facility may prepare larger batches without individual prescriptions, registers with the FDA, and is subject to current good manufacturing practice requirements. Neither route produces an FDA-approved product.
That last sentence is the one most often blurred. Registration is not approval. Inspection is not approval. Operating legally is not approval. Approval is a specific determination that the FDA has reviewed evidence of safety, effectiveness, and manufacturing quality for a particular product before it is marketed, and no compounded preparation has been through that process.
| Term | What it actually means | What it does not mean |
|---|---|---|
| FDA approved | The agency reviewed safety, efficacy and quality evidence before marketing | Applies to any compounded preparation |
| FDA registered | The facility filed a registration with the agency | The product was reviewed or approved |
| FDA inspected | The agency conducted a facility inspection | The product was approved, or that the inspection found no problems |
| State licensed | A state board authorised the pharmacy to operate | Any federal review of the product |
| cGMP compliant | The facility follows manufacturing practice standards | The specific product was evaluated for safety or efficacy |
| Third-party tested | A laboratory analysed a sample | Systematic batch verification, unless the scope and frequency are disclosed |
What can a patient actually verify before paying?
Where randomised evidence is absent, verification of the supply chain takes its place as the meaningful check. The useful feature of these checks is that they are all things a reader can do independently, against public records, before any money changes hands.
| Check | How to do it | What a refusal or gap tells you |
|---|---|---|
| Pharmacy legal name | Ask the provider in writing before enrolling | A provider unwilling to name its pharmacy is withholding the single most useful fact |
| State licence | Search the licensing state board's public register | An unlisted or lapsed licence is disqualifying |
| 503A or 503B status | Ask, then check the FDA outsourcing facility register for 503B claims | A 503B claim absent from the register is a serious discrepancy |
| Disciplinary history | State board records and enforcement notices | Prior action is not automatically disqualifying but is material |
| Concentration in mg/mL | Ask before ordering; confirm on the dispensing label | An unwillingness to state concentration makes safe use impossible |
| Beyond-use date policy | Ask what date is assigned and on what basis | No stated policy suggests weak quality systems |
| Cold-chain and excursion policy | Ask who bears risk if a shipment arrives warm | No policy means the risk sits with you |
A provider that answers all seven readily has demonstrated something meaningful. One that treats these as intrusive has also answered, in a different way. This is not a guarantee of quality — it is the strongest signal available to a consumer in a market where the usual guarantee, regulatory approval, does not exist.
What are the limits of what this page can tell you?
This page describes a regulatory framework and a verification method. Both have limits that matter.
- Regulatory status changes, and enforcement priorities change with it. Statements here carry the verification date shown above.
- State licensing requirements differ, so a check that is straightforward in one state may be harder in another.
- Verification of a pharmacy's licence establishes that it is authorised to operate. It does not establish the quality of any particular preparation.
- No verification step available to a consumer substitutes for the premarket review that approved products undergo.
What does this page cover, and what does it deliberately leave out?
This page addresses Federal and state framework, shortage and enforcement and prescribing, organised around the primary question of tirzepatide compounding regulation. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Federal and state framework | Covered on this page | Regulatory or policy source |
| Shortage | Covered on this page | Regulatory or policy source |
| Enforcement and prescribing | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the dispensing pharmacy and your prescriber |
What are the limits of what this page can tell you?
Every page on this site rests on a specific regulatory position on compounded preparations, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the dispensing pharmacy and your prescriber.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide compounding regulation.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 7 technical terms this page uses, including 503A, 503B, GLP-1, beyond-use date — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| incretin | A gut hormone released in response to food that amplifies insulin secretion. GIP and GLP-1 are the two principal human incretins, and the drug class that mimics them is named after them. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
Frequently asked questions
Is compounding tirzepatide legal?
Compounding operates within a federal and state framework with restrictions on copying approved drugs. Current status should be checked against FDA and state board sources.
Why does drug shortage status matter?
It has historically been significant to what compounding is permissible, because a shortage means the approved product is unavailable.
Does regulation verify the product?
No. Facility oversight governs how an operation runs, not whether a given preparation is correct.
Where do I check current status?
FDA communications and state board of pharmacy records, rather than provider marketing.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.